Alkem Laboratories Ltd
ALKEMBSE 539523PharmaceuticalsMkt cap ₹62,652 Cr
Whole group, including subsidiaries — the figures companies headline.
Revenue · Q1 FY27
₹3,740 Cr
YoY +10.9%QoQ +3.8%
Net profit · Q1 FY27
₹521 Cr
YoY -22.0%QoQ +107.5%
Net margin · Q1 FY27
13.9%
-5.9 pts vs Q1 FY26
Net profit · FY26
₹2,351 Cr
YoY +6.1%
Quarterly results
| ₹ Cr | Q1 FY27 Apr–Jun 2026 | Q4 FY26 Jan–Mar 2026 | Q3 FY26 Oct–Dec 2025 | Q2 FY26 Jul–Sep 2025 | Q1 FY26 Apr–Jun 2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 3,740 | 3,603 | 3,737 | 4,001 | 3,371 | +10.9% |
| Other income | 153 | 200 | 143 | 104 | 136 | +11.9% |
| Total income | 3,893 | 3,803 | 3,880 | 4,105 | 3,508 | +11.0% |
| Profit before tax | 772 | 423 | 781 | 896 | 771 | +0.1% |
| Tax | 251 | 171 | 128 | 116 | 103 | +143.9% |
| Net profit | 521 | 251 | 653 | 779 | 668 | -22.0% |
| Net margin | 13.9% | 7.0% | 17.5% | 19.5% | 19.8% |
Annual results
| ₹ Cr | FY26 Apr 2025–Mar 2026 | FY25 Apr 2024–Mar 2025 | FY24 Apr 2023–Mar 2024 | FY23 Apr 2022–Mar 2023 | FY22 Apr 2021–Mar 2022 | YoY |
|---|---|---|---|---|---|---|
| Revenue | 14,712 | 12,965 | 12,668 | 11,599 | 10,634 | +13.5% |
| Other income | 583 | 494 | 311 | 216 | 163 | +18.1% |
| Total income | 15,296 | 13,458 | 12,978 | 11,815 | 10,797 | +13.7% |
| Profit before tax | 2,871 | 2,527 | 2,023 | 1,305 | 1,844 | +13.6% |
| Tax | 518 | 311 | 212 | 298 | 164 | +66.5% |
| Net profit | 2,351 | 2,215 | 1,811 | 1,007 | 1,680 | +6.1% |
| Net margin | 16.0% | 17.1% | 14.3% | 8.7% | 15.8% |
BIC's take
We haven't covered Alkem Laboratories Ltd yet. Browse our sector reports →
Source: BSE filings · Data as of 2 Oct 2026, 5:05 pm IST· ₹ crore unless stated. Covers BSE 500 companies only. Consolidated figures include subsidiaries; standalone is the parent company alone. Growth is shown only against a positive base. Not investment advice — check the company's full filing before acting.